Cell Cycle Harmony

This is the first track I wrote to test out the new Spitfire Audio Olafur Arnalds Cells library.  I added some Spitfire Jupter, Slate+Ash Primaries and Cycles, Pulse Audio Likkuva and Orchestral Tools Time Micro, Waverunner Audio Synth Atlantic, and Westwood Instruments Alt Piano to round it out.

From the First Cells

BUFFALO, NY - December 11, 2024 – A #news feature on the #research paper “Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition” by Rackear et al. was #published in Oncotarget's Volume 15 on November 22, 2024, titled “Advancements in cell-penetrating monoclonal antibody treatment."

This new publication by Sai Pallavi Pradeep and Raman Bahal from the  Department of Pharmaceutical Sciences at the University of Connecticut highlights significant advancements in monoclonal antibody (mAb) therapies. The focus is on the 3E10 antibody, originally derived from autoimmune mouse studies in systemic lupus erythematosus. Unlike traditional mAbs, which struggle to reach intracellular targets, this cell-penetrating antibody targets cancer cells by addressing a major limitation of current therapies. By targeting RAD51, a key intracellular protein involved in DNA repair, the 3E10 antibody shows great promise for cancer treatment, particularly in cancers with defective DNA repair pathways.

mAbs have already changed the landscape of cancer therapy, offering treatments that are more targeted and have fewer side effects compared to chemotherapy. However, current therapies are limited since mAbs only target proteins on the surface of cancer cells. This research pushes the boundaries by demonstrating how 3E10 antibodies can penetrate cells and access their internal molecules. This unique capability expands the potential of mAb therapies and targeted cancer treatments.

Different humanized versions of the 3E10 antibody were created and carefully tested. Some versions were particularly effective at blocking RAD51, while others showed promise for carrying other therapeutic molecules like genetic material into the cancer cells. This flexibility means that 3E10 could be used to treat different cancer types and deliver various therapeutic molecules directly into tumor cells. This progress offers exciting new possibilities for treating cancer tumors that are resistant to conventional therapies. 

In conclusion, the 3E10 antibody’s dual function—targeting DNA repair pathways and delivering therapeutic molecules—positions it as a transformative tool in cancer research and targeted cancer treatments.

DOI - https://doi.org/10.18632/oncotarget.28674

Correspondence to - Raman Bahal - raman.bahal@uconn.edu

Video short - https://www.youtube.com/watch?v=3uMdPvThFHA

Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28674

Subscribe for free publication alerts from Oncotarget: 
https://www.oncotarget.com/subscribe/

Keywords - cancer, monoclonal anti-bodies, cell penetration, nucleic acid delivery, 3E10

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Oncotarget

Breakthroughs in Cell-Penetrating Monoclonal Antibody Therapies

Remix by The Black Cat Project done December of 2024. Track has been in Private mode till April 20th of 2025. It is now Public on Soundcloud as of April 21st 2025.

Artwork:
*multi-dimensional color magik by digital artist: Tékhnē (variation of the original release artwork:)

Frame-Dragging definition:
also known as the Lense-Thirring effect, is a predicted effect of general relativity where a rotating mass distorts the spacetime around it, effectively "dragging" nearby objects into its rotation. This phenomenon, while subtle, is detectable in experiments and has implications for understanding the behavior of spacetime near rotating objects like black holes.

GAI BARONE - 'CELLS' (The Black Cat Project's Frame-Dragging Remix)

LISTEN MUSIC https://album.link/wnjfdck8dgpdf 🖤

LISTEN MUSIC🖤

Dead Skin Cells feat. Rottenscape - Transparent Death

Scientists have discovered that a genetic variant called KIT M541L may play an important role in a rare immune disorder known as #mastocytosis. The findings may help explain why some #patients develop more severe forms of the disease.

Understanding Mastocytosis

Mastocytosis is a condition where the body produces too many mast cells. These cells are part of the immune system and help the body fight infections, but in excess, they release chemicals that can cause itching, swelling, and even serious organ damage.

There are two main types of mastocytosis. The first is cutaneous mastocytosis, which mostly affects the skin. The second is systemic mastocytosis, a more serious form where mast cells build up in internal organs like the liver, spleen, and bone marrow.

The disease is linked to mutations in the KIT gene, which regulates mast cell growth. The most studied mutation is KIT D816V, but recent research has highlighted another variant, KIT M541L.

The Study: Impact of KIT M541L Variant

A team of researchers at the National Institutes of Health (NIH), led by first author Luisa N. Dominguez Aldama and corresponding author Melody C. Carter, aimed to better understand the prevalence and impact of the KIT M541L genetic variant in mastocytosis patients. The study published in Oncotarget on July 22, 2024, titled “Prevalence and impact of the KIT M541L variant in patients with mastocytosis,” examined the presence of the KIT M541L gene variant in 100 patients with mastocytosis, both adults and children, alongside 500 healthy individuals. 

By comparing these two groups, the researchers wanted to see if there was a relation between the KIT M541L variant and mastocytosis severity.

Full blog - https://www.oncotarget.org/2025/01/15/mastocytosis-key-insights-into-kit-m541l-gene-mutation/

Paper DOI - https://doi.org/10.18632/oncotarget.28614

Correspondence to - Melody C. Carter - mcarter@niaid.nih.gov

Video short - https://www.youtube.com/watch?v=zpiBbSfkTX4

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28614

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, mastocytosis, KIT M541L, KIT D816V, adults, pediatrics

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

Mastocytosis: Key Insights into KIT M541L Gene Mutation

BUFFALO, NY - February 24, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on February 18, 2025, titled “Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells."

Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins University School of Medicine studied the tumor-suppressing protein p53, which plays a key role in preventing cancer. Their findings reveal how p53 affects cancer cell growth, treatment resistance, and potential drug targets, providing new insights that could improve future cancer therapies.

The p53 protein plays a crucial role in preventing cancer by stopping uncontrolled cell growth. However, many cancers mutate or suppress p53, allowing tumors to develop and resist treatment. In this study, researchers restored p53 function in colorectal cancer cells, which led to slower cellular growth, increased cellular aging (senescence), and greater sensitivity to radiation therapy. These findings suggest that p53 status influences cancer progression and response to treatment, making it a promising target for new therapies.

The study also examined hTERT-RPE1 cells; a type of non-cancerous human cell used in research. When the TP53 gene was disrupted in these cells, they grew faster and became more resistant to radiation, reinforcing the idea that p53 helps prevent cancerous growth.

Another key discovery was a previously unnoticed p53 mutation (A276P) found in a subset of hTERT-RPE1 cells. This mutation weakened p53’s ability to regulate certain genes but did not affect its ability to control calcium signaling, a process important for cell survival. The unexpected appearance of this mutation suggests that even non-cancerous cells can acquire genetic changes that mimic early cancer development. This insight could help scientists better understand how cancers evolve and become resistant to treatment.

"Cancers that retain wild type TP53 presumably harbor other clonal alterations that permitted their precursors to bypass p53-mediated growth suppression."

A breakthrough in the study was the identification of two new p53-regulated genes that could be important for cancer treatment. The first, ALDH3A1, helps detoxify harmful substances and may impact cancer cell resistance to oxidative stress. The second, NECTIN4, is a protein found in many aggressive cancers, including bladder and breast cancer. Notably, NECTIN4 is the target of enfortumab vedotin, an FDA-approved drug for bladder cancer. These discoveries provide new potential drug targets and could lead to improved therapies for cancers that still retain some p53 function.

In conclusion, this research highlights the critical role of p53 in cancer biology and suggests that restoring p53 function could make tumors more vulnerable to radiation and chemotherapy. The discovery of new p53-controlled genes provides new opportunities for targeted cancer therapies. With further research, these findings could lead to new precision medicine strategies that leverage p53’s natural tumor-suppressing abilities.

DOI - https://doi.org/10.18632/oncotarget.28690

Correspondence to - Fred Bunz - fredbunz@jhmi.edu

Video short - https://www.youtube.com/watch?v=Psxj3ctbTuk

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

Researchers Identify New p53 Targets to Combat Cancer Growth

I will never quit Sm0king #nicotine #kush - (DJ HEROIN EXCLUSIVE)

BUFFALO, NY - March 3, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on February 28, 2025, titled “Effect of TIMPs and their minimally engineered variants in blocking invasion and migration of brain cancer cells."

Elham Taheri and Maryam Raeeszadeh-Sarmazdeh from the University of Nevada, Reno, explored a new approach to slowing the spread of glioblastoma multiforme (GBM), the most aggressive and deadly form of brain cancer. Their study highlights the potential of both natural and engineered molecules to block cancer cell movement, offering a promising strategy to combat this challenging disease.

Glioblastoma multiforme is difficult to treat because it quickly spreads into healthy brain tissue, making complete surgical removal nearly impossible. A major driver of this invasive behavior is a group of enzymes called matrix metalloproteinases (MMPs), which break down surrounding tissue and create space for cancer cells to spread. Among them, MMP-9 plays a particularly significant role in GBM progression and resistance to current treatments.

To address this challenge, the researchers investigated tissue inhibitors of metalloproteinases (TIMPs), natural MMP blockers, and specially engineered versions designed for better effectiveness. The study used cell line models of GBM to test both TIMP-1 and TIMP-3 and their engineered counterparts (mTC1 and mTC3), specific blockers of MMP-9. 

“Our study focused on minimal TIMP variants, due to their small molecular size and potential in higher cellular uptake and delivery, to assess their potential in cell-based assays.”

The results indicated that the engineered TIMPs were just as effective as, or even better than, the natural ones at reducing cancer cell migration and invasion. These findings are particularly promising because previous attempts to block MMPs with small-molecule drugs faced challenges such as poor selectivity and unwanted side effects. In contrast, these engineered TIMPs offer a more targeted and potentially safer approach.

One of the greatest obstacles in treating brain cancer is delivering drugs across the blood-brain barrier, a protective layer that prevents many therapeutic compounds from reaching the brain. To address this, the researchers used cell-penetrating peptides to help the TIMP variants reach and enter cancer cells more effectively. Their results confirmed that the engineered TIMPs successfully reached tumor cells, further increasing their potential as a treatment.

Additionally, the study found that these engineered TIMPs did not significantly affect healthy cells at lower doses, suggesting they could be used safely. This makes them strong candidates for further drug development.

These findings could lead to new treatment options for GBM, a cancer with very few effective therapies. Future research will focus on testing these TIMP variants in animal models to evaluate their long-term effects and safety. Researchers also plan to investigate whether combining these engineered TIMPs with existing treatments, such as chemotherapy or immunotherapy, could improve outcomes.

In summary, given the aggressive nature of GBM and the urgent need for better therapies, this study represents an important step forward. If further research confirms these results, engineered TIMPs could become a valuable tool in the fight against brain cancer, offering new hope for improved treatments and patient survival.

DOI - https://doi.org/10.18632/oncotarget.28691

Correspondence to - Maryam Raeeszadeh-Sarmazdeh - maryamr@unr.edu

Video short - https://www.youtube.com/watch?v=tdBlkOX50D8

To learn more about Oncotarget, please visit https://www.oncotarget.com.

MEDIA@IMPACTJOURNALS.COM

Engineered TIMP Molecules Show Potential to Slow Glioblastoma Brain Cancer Spread

Chris Holman welcomes Chris Miller, SIOR, Senior Vice President, Martin Commercial Properties, Lansing, MI.

This discussion is the first of three with Martin Commercial Properties team, and focuses on Industrial and Investment Advisory.

These were the questions they cover in this conversation: 
With industrial vacancy rates holding steady, what factors are driving demand in the market, and how do you see this trend evolving in 2025?

How are companies in the industrial sector adapting to supply chain challenges, and what role does location selection play in mitigating these risks?

With major investments from companies like GM, Neogen, and Gestamp, how do these large-scale projects impact industrial property development and investor confidence?

These interviews grow out of a series of three recent reports recently released by the company. You can access them at: https://martincommercial.com/marketinsights/ .

Industrial '24 Market Insights: "INDUSTRIAL ‘24 Market Insights Greater Lansing Area, Michigan | H2 2024"​

The Greater Lansing Area industrial market experienced an increase in the average vacancy rate for leased industrial space, rising from 8.9% in H1 2024 to 11.5% in H2 2024. This increase was primarily driven by significant vacancies in the South Submarket, which saw its vacancy rate jump to 26.5%.  Despite this, the overall market remains strong with healthy demand across most properties, particularly in the West Submarket, which boasts a low vacancy rate of 1.4% and positive net absorption of 63,096 SF. ​

Key developments in the market include Temperpack Technologies leasing 135,000 SF in the West Submarket, General Motors securing a $500 million federal grant for its Lansing Grand River plant, and the ongoing construction of Ultium Cells' 2.8 million SF battery plant.   Additionally, Neogen and Gestamp are making significant investments in new facilities, further indicating strong investor confidence in the region.  The largest owner-user sales in H2 2024 were 65,000 SF at 3366 Remy Dr. for $2.2 million and 55,000 SF at 2200 Olds for $1.1 million. ​

Absorption in the Greater Lansing industrial market totaled -179,614 SF in H2 2024, with the South Submarket experiencing the most significant negative absorption due to large vacancies.  The North Submarket remained relatively stable with minimal changes and no major leases signed.  Overall, the Greater Lansing Area continues to be viewed as a stable and promising market for long-term investment, supported by ongoing developments and strong demand in key submarkets. Investors and occupiers continue to view the Greater Lansing Area as a stable and promising market for long-term investment."

» Visit MBN website: www.michiganbusinessnetwork.com/
» Subscribe to MBN’s YouTube: www.youtube.com/@MichiganbusinessnetworkMBN
» Like MBN: www.facebook.com/mibiznetwork
» Follow MBN: twitter.com/MIBizNetwork/
» MBN Instagram: www.instagram.com/mibiznetwork/

Michigan Business Beat | Chris Miller, Martin Commercial Properties - Industrial/Investment Advisory

Da Universe is Mental

Time to spice up the topic of cell division with this hit from the Learning Thru Music: Science Notes library! From Interphase to Telophase, Mitosis will get your Science students singing and up on their feet! Also included the download from the Learning Thru Music Teachers Pay Teachers store are activities and assessments to accompany the song as well as the instrumental version! We've also added a genres of music activity package!


Science Notes

Mitosis

Video: https://www.youtube.com/watch?v=ZV4yD5XYgMI

Cells

A new study from the Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins University School of Medicine, published in Oncotarget, reveals that the gene p53, long known as the “guardian of the genome,” may be even more powerful than previously thought. By studying it in non-cancerous human cells, researchers discovered how p53 stops risky cell growth and uncovered two new potential targets for cancer therapy.

Understanding p53: The Genome’s Guardian Against Cancer

The p53 gene is one of the most important natural defenses our body has against cancer. When functioning properly, p53 detects damage in a cell’s DNA and either stops the cell from dividing or pushes it to self-destruct. This process helps prevent potentially dangerous mutations from spreading. However, many cancers find ways to silence or mutate p53, allowing uncontrolled growth and resistance to treatments.

Studying p53 in a clear and accurate way has long been a challenge. Most cancer cell models used in research already carry numerous genetic mutations, which can mask or alter how p53 truly functions. To fully understand this vital tumor-suppressing gene, scientists needed a model that closely resembled healthy, genetically stable human cells—yet could still be maintained and studied over time in the laboratory.

The Study: Exploring p53 in Normal and Cancer Cell Models

Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz explored p53 activity using a uniquely suitable cell line: hTERT-RPE1. These non-cancerous human cells are immortalized using telomerase, meaning they continue dividing like cancer cells, but without the chaotic mutations seen in tumors. This makes them an excellent model for studying how p53 operates in near-normal conditions.

Full blog - https://www.oncotarget.org/2025/04/22/new-insights-into-p53-a-powerful-genes-role-in-cancer-therapy/

Paper DOI - https://doi.org/10.18632/oncotarget.28690

Correspondence to - Fred Bunz - fredbunz@jhmi.edu

Video short - https://www.youtube.com/watch?v=Psxj3ctbTuk

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28690

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, p53, ionizing radiation, immortalized cells, ALDH3A1, NECTIN4

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

New Insights into p53: A Powerful Gene’s Role in Cancer Therapy

Get your Science students singing and creating gestures and dances to this hit from the Learning Thru Music: Science Notes library! Accompanying the song on the Learning Thru Music Teachers Pay Teachers store are activities and assessments to further engage student learning of the differences between plant and animal cells! Also included is the instrumental version along with a genres of music activity package! Enjoy this addition to your elementary science program!


Plant and Animal Cells

Hailing from Sydney, Australia, artist Pannotia, under the Pure Space label, is releasing a five-track EP titled "Cell." This EP will be available on Bandcamp from 2nd May and immediately captivates with its own twang. This sound exists within a multitude of spaces, specifically in a realm called ‘Biozone’ in which this track is titled.

The music evokes a feeling of being recharged, discovering movements and forms that have always existed within but are now imbued with cosmic influence. Bionic and poetic, it offers an undeniably sexy slow groove that holds a special place on the dance floor, built upon bass-heavy foundations and a seductive, relaxed trance – a track capable of transporting us in any direction as it draws to a close.

@pannotia
@purespacefm

www.instagram.com/purespacefm/

Write up by @danpeplow

Follow us on social media:
@itsdelayed
www.itsdelayed.com
www.facebook.com/itsdelayed
www.instagram.com/_____delayed/
linktr.ee/delayed
www.youtube.com/@_____delayed

PREMIERE: Pannotia - Biozone [Pure Space]

Life Pharm Is a California company that empowers people to regenerate their health and their wealth.

Life Pharm Regeneration Company

Medical Missionary Sharing the Healing Message of the Gospel of Jesus Christ

Delayed is a source of deep, minimal, and micro house, techno, ambient and beyond. Follow us for new mixes, fresh releases, and exclusive interviews with distinguished and rising artists.

Founded in Brooklyn and run by a team of music producers, DJs, and perpetual music addicts.

Learning Thru Music: Science Notes
Science. Music. Fun!

The Home of Business in Michigan. Get on-demand access to audio programs, articles and resources presented by savvy business leaders and industry experts.

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

https://www.beatport.com/label/0ut/103448 <3
0UT is an independent record label 🌑
Release music & arts of underground artists worldwide
The mind escape of art control...
ＭＵＳＩＣ ＦＲＯＭ ＡＮＯＴＨＥＲ ＳＩＤＥ 
Send your demo to: label0UT@gmail.com
/// //// /// //// /// //// /// //// /// 
ARTISTS: 
@d3bau4
@night_mess
@coil_circuit
@theendofsunnydays
@satoruumus
@skele7
@xff771
@deescawa
@dltplz
@iTEXHO
@blackvv
⊷⊷⊷⊷⊷⊷⊷⊷⊷⊷⊷⊷⊷⊷⊷⊷
#electronic #alternative #techno
#idm #house #dubstep #ambient
МУЗЫКА ВСЕГ0
⁖ Founded by d3bAU4

©℗ 0UTRecords

check out our new TWITCH channel! :)
 https://www.twitch.tv/demetri_nocturnal


www.soundcloud.com/nanonaut
PURCHASE HIGH QUALITY DOWNLOADS
here: https://heavyweightsoundrecordings.bandcamp.com/

VISIT THE MIXCLOUD PAGE ALSO:
https://www.mixcloud.com/HEAVYWEIGHT_SOUND_RECORDINGS

New tracks tagged #cells